Orthocell Limited (OCC.AX)
AUD 1.45
(-1.69%)
AUD 1.45
(-1.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -11.68 Million AUD | -13.3% |
| 2023 | -10.3 Million AUD | 10.54% |
| 2022 | -11.52 Million AUD | 1.24% |
| 2021 | -11.66 Million AUD | -23.23% |
| 2020 | -9.46 Million AUD | -11.19% |
| 2019 | -8.51 Million AUD | -6.03% |
| 2018 | -8.03 Million AUD | -30.29% |
| 2017 | -6.16 Million AUD | -15.13% |
| 2016 | -5.35 Million AUD | -6.58% |
| 2015 | -5.02 Million AUD | -84.18% |
| 2014 | -2.72 Million AUD | -102.37% |
| 2013 | -1.34 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -11.68 Million AUD | -13.3% |
| 2024 Q2 | -5.94 Million AUD | 0.0% |
| 2024 Q4 | -4.57 Million AUD | 0.0% |
| 2023 FY | -10.3 Million AUD | 10.54% |
| 2023 Q2 | -5.35 Million AUD | 0.0% |
| 2023 Q4 | -4.98 Million AUD | 0.0% |
| 2022 Q2 | -4.73 Million AUD | 0.0% |
| 2022 Q4 | -6.79 Million AUD | 0.0% |
| 2022 FY | -11.52 Million AUD | 1.24% |
| 2021 FY | -11.66 Million AUD | -23.23% |
| 2021 Q4 | -4.65 Million AUD | 0.0% |
| 2021 Q2 | -7.01 Million AUD | 0.0% |
| 2020 FY | -9.46 Million AUD | -11.19% |
| 2020 Q4 | -4.43 Million AUD | 0.0% |
| 2020 Q2 | -5.02 Million AUD | 0.0% |
| 2019 FY | -8.51 Million AUD | -6.03% |
| 2019 Q4 | -4.57 Million AUD | 0.0% |
| 2019 Q2 | -3.93 Million AUD | 0.0% |
| 2018 Q2 | -3.2 Million AUD | 0.0% |
| 2018 FY | -8.03 Million AUD | -30.29% |
| 2018 Q4 | -4.82 Million AUD | 0.0% |
| 2017 FY | -6.16 Million AUD | -15.13% |
| 2017 Q2 | -2.86 Million AUD | 0.0% |
| 2017 Q4 | -3.29 Million AUD | 0.0% |
| 2016 Q2 | -2.37 Million AUD | 0.0% |
| 2016 Q4 | -2.97 Million AUD | 0.0% |
| 2016 FY | -5.35 Million AUD | -6.58% |
| 2015 Q2 | -2.82 Million AUD | 0.0% |
| 2015 Q4 | -2.2 Million AUD | 0.0% |
| 2015 FY | -5.02 Million AUD | -84.18% |
| 2014 FY | -2.72 Million AUD | -102.37% |
| 2014 Q4 | -2.38 Million AUD | 0.0% |
| 2014 Q2 | -344.07 Thousand AUD | 0.0% |
| 2013 FY | -1.34 Million AUD | 0.0% |
| 2013 Q3 | - AUD | 100.0% |
| 2013 Q4 | -600.17 Thousand AUD | 0.0% |
| 2013 Q2 | -747.71 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | -122.007% |
| Acrux Limited | -9.83 Million AUD | -18.783% |
| Race Oncology Limited | -13.38 Million AUD | 12.701% |
| Biome Australia Limited | -1.91 Million AUD | -510.541% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 20.536% |
| BTC Health Limited | 1.05 Million AUD | 1206.914% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 5.106% |
| CSL Limited | 5.64 Billion AUD | 100.207% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 73.926% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 123.767% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 220.219% |
| Hexima Limited | -1 Million AUD | -1057.98% |
| Immutep Limited | -44.93 Million AUD | 74.006% |
| Memphasys Limited | -2.7 Million AUD | -331.994% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 105.17% |
| Noxopharm Limited | -7.53 Million AUD | -55.025% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -62.544% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 75.257% |
| Starpharma Holdings Limited | -15.15 Million AUD | 22.943% |
| Tissue Repair Ltd | -4.87 Million AUD | -139.566% |
| Biotron Limited | -5.15 Million AUD | -126.766% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 40.408% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -700.555% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -281.429% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -96.71% |
| Patrys Limited | -3.53 Million AUD | -230.054% |
| Imugene Limited | -140.93 Million AUD | 91.711% |
| PYC Therapeutics Limited | -38.85 Million AUD | 69.938% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | -61.53% |
| Cynata Therapeutics Limited | -8.8 Million AUD | -32.621% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -62.395% |
| Nanollose Limited | -1.24 Million AUD | -834.62% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -447.477% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -467.993% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -163.982% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -306.472% |
| Nyrada Inc. | -4.56 Million AUD | -156.146% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 53.387% |
| PharmAust Limited | -6.65 Million AUD | -75.428% |
| AnteoTech Limited | -11.72 Million AUD | 0.388% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 82.06% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 47.027% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -154.536% |
| Actinogen Medical Limited | -12.83 Million AUD | 9.018% |
| Immuron Limited | -5.8 Million AUD | -101.36% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -105.972% |